IL282485B2 - Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53 - Google Patents

Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53

Info

Publication number
IL282485B2
IL282485B2 IL282485A IL28248521A IL282485B2 IL 282485 B2 IL282485 B2 IL 282485B2 IL 282485 A IL282485 A IL 282485A IL 28248521 A IL28248521 A IL 28248521A IL 282485 B2 IL282485 B2 IL 282485B2
Authority
IL
Israel
Prior art keywords
composition
tumor
inhibitor
lenalidomide
mdm4
Prior art date
Application number
IL282485A
Other languages
English (en)
Hebrew (he)
Other versions
IL282485B1 (en
IL282485A (en
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of IL282485A publication Critical patent/IL282485A/en
Publication of IL282485B1 publication Critical patent/IL282485B1/en
Publication of IL282485B2 publication Critical patent/IL282485B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL282485A 2018-10-30 2019-10-28 Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53 IL282485B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862752382P 2018-10-30 2018-10-30
PCT/US2019/058319 WO2020092221A1 (en) 2018-10-30 2019-10-28 Method of treatment of p53 wt tumors

Publications (3)

Publication Number Publication Date
IL282485A IL282485A (en) 2021-06-30
IL282485B1 IL282485B1 (en) 2025-05-01
IL282485B2 true IL282485B2 (en) 2025-09-01

Family

ID=68582462

Family Applications (1)

Application Number Title Priority Date Filing Date
IL282485A IL282485B2 (en) 2018-10-30 2019-10-28 Compositions containing an mdm2 inhibitor and a cka1 inhibitor and/or an mdm4 inhibitor for use in the treatment of tumors with non-mutant p53

Country Status (10)

Country Link
US (1) US12115151B2 (cg-RX-API-DMAC7.html)
EP (1) EP3873460B1 (cg-RX-API-DMAC7.html)
JP (2) JP7653907B2 (cg-RX-API-DMAC7.html)
KR (1) KR102879859B1 (cg-RX-API-DMAC7.html)
CN (1) CN112996503A (cg-RX-API-DMAC7.html)
AU (1) AU2019369216B2 (cg-RX-API-DMAC7.html)
CA (1) CA3115716A1 (cg-RX-API-DMAC7.html)
ES (1) ES2986421T3 (cg-RX-API-DMAC7.html)
IL (1) IL282485B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020092221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
CN115216514B (zh) * 2022-08-01 2026-03-17 中国科学技术大学 Vam6(Vps39)作为靶点在药物筛选、基因编辑以及疾病治疗中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3541387T3 (pl) * 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
LIAO GUOCHAO ET AL,, THE DEVELOPMENT OF PIPERIDINONES AS POTENT MDM2-P53 PROTEIN-PROTEIN INTERACTION INHIBITORS FOR CANCER THERAPY, 18 September 2018 (2018-09-18) *
LINDNER STEFANIE ET AL,, THE MOLECULAR MECHANISM OF THALIDOMIDE ANALOGS IN HEMATOLOGIC MALIGNANCIES, 5 August 2016 (2016-08-05) *
MAXIMILIAN STAHL ET AL,, LENALIDOMIDE USE IN MYELODYSPLASTIC SYNDROMES: INSIGHTS INTO THE BIOLOGIC MECHANISMS AND CLINICAL APPLICATIONS : USE OF LENALIDOMIDE IN MDS: BIOLOGY AND EFFICACY, 13 February 2017 (2017-02-13) *
PAOLA SECCHIERO ET AL,, RECENT ADVANCES IN THE THERAPEUTIC PERSPECTIVES OF NUTLIN-3, 1 February 2011 (2011-02-01) *
TOLEDO ET AL,, MDM2 AND MDM4: P53 REGULATORS AS TARGETS IN ANTICANCER THERAPY, 10 July 2007 (2007-07-10) *

Also Published As

Publication number Publication date
JP2025026846A (ja) 2025-02-26
JP2022505884A (ja) 2022-01-14
CA3115716A1 (en) 2020-05-07
IL282485B1 (en) 2025-05-01
KR20210087958A (ko) 2021-07-13
US20210379039A1 (en) 2021-12-09
AU2019369216A1 (en) 2021-05-20
IL282485A (en) 2021-06-30
KR102879859B1 (ko) 2025-11-04
JP7653907B2 (ja) 2025-03-31
EP3873460A1 (en) 2021-09-08
AU2019369216B2 (en) 2022-05-19
EP3873460B1 (en) 2024-06-12
WO2020092221A1 (en) 2020-05-07
US12115151B2 (en) 2024-10-15
CN112996503A (zh) 2021-06-18
ES2986421T3 (es) 2024-11-11

Similar Documents

Publication Publication Date Title
Cufi et al. Autophagy positively regulates the CD44+ CD24-/low breast cancer stem-like phenotype
Agnarelli et al. IRF4 in multiple myeloma—Biology, disease and therapeutic target
Synnott et al. Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Abraha et al. Apoptotic pathways as a therapeutic target for colorectal cancer treatment
Duffy et al. p53 as a target for the treatment of cancer
Crombet Ramos et al. Nimotuzumab for patients with inoperable cancer of the head and neck
JP2024074801A5 (cg-RX-API-DMAC7.html)
Hoffmann Systemic therapy strategies for head-neck carcinomas: Current status
BR112022008534A2 (pt) Compostos, composição farmacêutica, conjugado e métodos para tratar câncer e para tratar um distúrbio relacionado à proteína ras
Kumar et al. Current therapeutic strategies and challenges in NSCLC treatment: A comprehensive review
Wang et al. New strategies in esophageal carcinoma: translational insights from signaling pathways and immune checkpoints
Molyer et al. SMAC mimetics as therapeutic agents in HIV infection
IL282485B1 (en) Compositions containing an MDM2 inhibitor and a CKa1 inhibitor and/or an MDM4 inhibitor for use in the treatment of tumors with non-mutant p53
US20160122408A1 (en) Galectin-3 Inhibitor (Gal-3M) is Associated with Additive Anti-Myeloma and Anti-Solid Tumor Effects, Decreased Osteoclastogenesis and Organ Protection when Used in Combination with Proteasome Inhibitors
Lei et al. A novel IgM–H-Ficolin complement pathway to attack allogenic cancer cells in vitro
Weekes et al. Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors
Djerf et al. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839)
Ge et al. Synergistic antitumor effects of CDK inhibitor SNS‑032 and an oncolytic adenovirus co‑expressing TRAIL and Smac in pancreatic cancer
Iizuka et al. APOBEC 3G is increasingly expressed on the human uterine cervical intraepithelial neoplasia along with disease progression
Bai et al. Phase Ib study of anti-EGFR antibody (SCT200) in combination with anti-PD-1 antibody (SCT-I10A) for patients with RAS/BRAF wild-type metastatic colorectal cancer
Zhang et al. Synergistic effect of subtoxic-dose cisplatin and TRAIL to mediate apoptosis by down-regulating decoy receptor 2 and up-regulating caspase-8, caspase-9 and Bax expression on NCI-H460 and A549 Cells
Tomao et al. Cervical cancer: are there potential new targets? An update on preclinical and clinical results
Zheng et al. The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells
AU2018244677A1 (en) Antibody binding specifically to N-terminal region of lysyl-tRNA synthetase exposed on cell membrane
Morales et al. Wilms’ tumor 1 (WT1) antigen is overexpressed in Kaposi Sarcoma and is regulated by KSHV vFLIP